Copy Link Print Information

Mivebresib

(Synonyms: ABBV-075)
15 Cited Publications
Avis client

Based on 15 publication(s) in Google Scholar

Mivebresib (ABBV-075) is a potent and orally active bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a Ki of 1.5 nM.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.29%
  • CAS No.: 1445993-26-9
  • Formule: C22H19F2N3O4S
  • Masse moléculaire:459.47
  • Stockage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Mivebresib Chemical Structure
    Mivebresib Chemical Structure
  • Experimental Validation Results for Mivebresib
  • Experimental Validation Results for Mivebresib
  • Experimental Validation Results for Mivebresib
  • Experimental Validation Results for Mivebresib
  • Experimental Validation Results for Mivebresib
  • Experimental Validation Results for Mivebresib
  • Experimental Validation Results for Mivebresib
  • Experimental Validation Results for Mivebresib
  • Experimental Validation Results for Mivebresib
CAS No.: 1445993-26-9
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Mivebresib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Pureté et documentation
  • Références
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Mivebresib

More
Customer Validation & Images
RT-PCRWBFlow CytometryCell Proliferation/Viability Assay
  • RT-PCR
  • WB
  • Flow Cytometry
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • WB
  • RT-PCR
  • WB

Voir tous les produits spécifiques à Isoform Epigenetic Reader Domain

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Mivebresib Chemical Structure
    Mivebresib Chemical Structure
    1/16
  • 1/16

    Mivebresib purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Dec 19. [Abstract]

    Customer Validation
     UCSD-AML1 and AML194 cells were treated with 500 nM of mivebresib as biologic replicates for 16 h. Total RNA was isolated and utilized for cDNA generation and qPCR analysis. Messenger RNA expression is normalized to GAPDH and expressed relative to the DMSO control cells. Columns, mean of three replicates; Bars, standard error of the mean (S.E.M.).

  • 1/16

    Mivebresib purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Dec 19. [Abstract]

    Customer Validation
     AML191, AML194, and UCSD-AML1 cells were treated with the indicated concentrations of Mivebresib (100-1000 nM) for 24 h. At the end of treatment, cells were harvested, total cell lysates were prepared, and immunoblot analyses were conducted. The expression levels of β-Actin in the total cell lysates served as the loading control. Representative blots of at least two experiments are shown.

  • 1/16

    Mivebresib purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Dec 19. [Abstract]

    Customer Validation
     MUTZ-3, UCSD-AML1, AML191 and AML194 cells were treated with the indicated concentrations of Mivebresib (50-1000 nM) for 48 h. Following this, cells were stained with annexin V-FITC and TO-PRO-3 iodide and the % apoptotic cells were analyzed by flow cytometry.

  • 1/16

    Mivebresib purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Jul 3;43(7):114431. [Abstract]

    Customer Validation
     The cell viability of C4-2/tet-PLK1 cells upon dosages of ABBV-075 (Mivebresib) treatment. ** P < 0.01.

  • 1/16

    Mivebresib purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2022 Jun 11;239:114519. [Abstract]

    Customer Validation
     Protein levels of IDO1 and c-Myc. Ty-82 cells were treated with ABBV-075 (Mivebresib, 0.1-10 nM), or 21 for 24 h and collected for Western blotting.

  • 1/16

    Mivebresib purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2021 Mar:185:114435. [Abstract]

    Customer Validation
     Protein levels of IDO1 and c-Myc. Ty-82 cells were treated with 8124-053, ABBV-075 (Mivebresib, 0.1-10 nM), or N2817 for 24 h and collected for western blotting.

  • 1/16

    Mivebresib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Jul 19;10(8):557. [Abstract]

    Customer Validation
     BET inhibitors reduce IDO1 transcription.The protein levels of IDO1 are determined by RT-qPCR and western blotting, respectively.

  • 1/16

    Mivebresib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Jul 19;10(8):557. [Abstract]

    Customer Validation
     ABBV-075 (Mivebresib, 10-100 nM; 3-24 h) reduces the mRNA levels of IDO1 in concentration- and time-dependent manners in Ty-82 cells.

  • 1/16

    Mivebresib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Jul 19;10(8):557. [Abstract]

    Customer Validation
     ABBV-075 (Mivebresib, 10-100 nM; 3-24 h) reduces the protein levels of IDO1 in concentration- and time-dependent manners in Ty-82 cells.

  • Mivebresib